Drug profile · INN
ropivacaine hydrochloride
ROPIVACAINE HYDROCHLORIDE
ropivacaine hydrochloride (ROPIVACAINE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — ropivacaine hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 8
- Data quality
- 0.89
Quick answer
ropivacaine hydrochloride (ROPIVACAINE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ropivacaine hydrochloride?
ropivacaine hydrochloride (ROPIVACAINE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ropivacaine hydrochloride?
ROPIVACAINE HYDROCHLORIDE is a marketed brand name for ropivacaine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ropivacaine hydrochloride?
ropivacaine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.